United States 
United States
As new technologies are developed around the use of mRNA, exciting applications emerge. TriLink is a proven leader in supporting cutting-edge mRNA research, from unique raw materials to custom synthesis. Join TriLink technical experts, Taylor McReynolds, MS and Cory Smith for this workshop on several noteworthy applications supported by TriLink mRNA services, including base editing, riboswitches, pandemic response and more.
From sequencing to therapeutics, NTPs are utilized in a wide range of applications. Hundreds of different modified NTPs are available as catalog products, and it can be overwhelming to find the right NTP for your project. In this workshop, TriLink technical experts Nick Ko and Taylor McReynolds, MS, will discuss the various different NTP modifications that exist and how to best utilize them to benefit your research, with a special emphasis on optimizing mRNA for therapeutic applications.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses synthesizing self-amplifying RNA vaccines to improve yields and accelerate GMP manufacturing.
In this presentation Jessica Madigan, Director of Business Development will discuss, investigative mRNA vaccine programs scale from target-centric research to progressing candidates through the drug development process, challenges arise when determining the optimal path forward.
This webinar presented by Dr. Anton McCaffrey will focus on the uses and value of CleanCap AU. CleanCap Reagent AU is designed for the co-transcriptional capping of mRNA to produce an mRNA with naturally occurring Cap 1.
We are pleased to introduce a new type of educational event. The TriLink SpotLight Workshops are designed to be focused and impactful sessions with topic experts that allow you to learn and interact with Q&A. Our first workshop is on our proprietary mRNA capping technology — CleanCap® featuring Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies.
In this Webinar Dr. Tal Zaks, CMO at Moderna, will discuss vaccine and trial efforts against COVID-19
In this webinar, you will hear from Dr. Andy Geall about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat.
In this Webinar Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group at the Mayo Clinic will discuss, SARS-CoV-2: Going Viral.
In this presentation, Dr. Nicole Gaudelli will discuss how her group has transformed off-the-shelf base editors from a technology developed in academia to a promising therapeutic tool through engineering, screening, and directed evolution.
In this Webinar Dr. Mark Kehrli, Center Director at the National Animal Disease Center will discuss, Coronaviruses in Livestock: Vaccines and International Transport of Viruses.
In this Webinar Dr. Barney S. Graham, Deputy Director, VRC, NIAID NIH will discuss, COVID-19: A prototype pathogen demonstration project for pandemic preparedness.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the benefits of using mRNA for manufacturing therapeutics.
In this webinar, T.J. Cradick, PhD, who was until recently head of genome editing at CRISPR Therapeutics, will introduce how genome editing is used to engineer cell therapies.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, mRNA applications, including gene engineering, gene replacement and immunobiology.
In this webinar, Dr. Wen Xue, Assistant Professor, RNA Therapeutics Institute at the University of Massachusetts Medical School will present, a modular delivery strategy for homology-directed repair by combining lipid nanoparticle delivery of Cas9 mRNA with adeno-associated viruses (AAV) encoding a sgRNA and a repair template.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the biology behind mRNA therapeutics.
This panel focuses on the lessons learned from COVID-19 vaccine human trials to date: our current understanding on the evolving trial data, neutralizing antibodies and safety of these COVID-19 vaccine candidates.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses planning, manufacturing design considerations and processes involved with research and clinical applications.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the cap structures .m6Am, Cap 0, Cap 1, and Cap 2 for optimal mRNA synthesis.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses the capping characteristics, capping methods and comparison data between legacy capping methods ARCA, and CleanCap®, TriLink’s, novel, new capping technology.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses chemical modification of mRNA including purification methods and sequence engineering.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, the Design & Manufacturing of Chemically Modified mRNA Therapeutics: This complete video highlights mRNA therapeutic manufacturing from research to clinical applications.
In this video Dr. Anton McCaffrey, Senior Director of Emerging Science and Innovation, at TriLink BioTechnologies discusses, the path to GMP production including planning and timelines.
In this video James Dahlman, PhD, Assistant Professor, Department of Biomedical Engineering at the Georgia Institute of Technology discusses, RNA therapeutics and the role of in vivo DNA barcoding in nanoparticle selection.
